Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise both to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
AB928, the first and only dual adenosine receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, lung, breast, colon, and pancreatic cancers.
AB680, the first CD73 small-molecule inhibitor in the clinic, is in Phase 1/1b development for the treatment of first-line metastatic pancreatic cancer.
AB154, an anti-TIGIT monoclonal antibody, is entering Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with anti-PD-1 (Zimberelimab) and AB928.
Zimberelimab, an anti-PD-1 monoclonal antibody, was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.